Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions: Risk reduction, Medical records-based recommendation, Algorithm-based recommendation; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 17 Years and older
Enrollment: 117,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC); Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Influenza
Interventions: Pasteurized milk contaminated with killed A(H5) virus; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza, Vaccination
Interventions: Text message influenza vaccine reminders; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 8 Years
Enrollment: 2,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania

Conditions: Flu, Human, Influenza, Human, Covid19
Interventions: Video about safety and effectiveness of adult seasonal flu vaccination; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years to 51 Years · Male only
Enrollment: 3,245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Influenza
Interventions: Fluarix™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,054 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Mobile, Alabama • Delray Beach, Florida • Pembroke Pines, Florida + 6 more

Conditions: Pandemic Influenza Immunization, Healthy Volunteers
Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more

Conditions: COVID-19 Respiratory Infection, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Influenza Viral Infections
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10,034 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Monovalent Frozen FluMist®, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Healthy Volunteers
Interventions: Immulina TM, Placebo; Drug · Dietary Supplement
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Influenza, Human, Immune Response
Interventions: Flucelvax inactivated influenza vaccine, Fluzone inactivated influenza vaccine; Biological
Lead sponsor: Richard Zimmerman MD; Other
Eligibility: 4 Years to 20 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Influenza, Virus Diseases
Interventions: H6N1 Teal HK 97/AA ca recombinant vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Influenza
Interventions: Fluarix; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 17 Years to 55 Years
Enrollment: 2,018 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2023
U.S. locations: 5
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more

Conditions: Influenza, Pneumonia
Interventions: oseltamivir; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 1,107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: Louisville, Kentucky

Conditions: Covid19, Influenza, Respiratory Tract Infections, Acute Respiratory Tract Infection, Acute Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, Respiratory Viral Infection
Interventions: Point-of-care molecular testing and treatment of influenza; Combination Product
Lead sponsor: University of Washington; Other
Eligibility: 3 Months and older
Enrollment: 1,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Burien, Washington • Seattle, Washington

Conditions: Influenza
Interventions: MK-1406, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 135
States / cities: Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 116 more

Conditions: Influenza
Interventions: Live Attenuated Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Adult Stem Cell Hematopoetic Transplant
Interventions: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine; Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Encouraging Flu Vaccination Among High-Risk Patients Identified by ML

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

H5N1 Milk Detection Study

Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine

Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

Infection Watch Study

A Clinical Study to Assess the Safety of a New Influenza Vaccine

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Immunologic Response to Influenza Vaccination in Children and Adolescents

Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

Fluarix Immunogenicity and Safety Trial

Acute Respiratory Infection Consortium

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform

Test-and-treat for Influenza in Homeless Shelters

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

Revealing Protective Immunity to Influenza Using Systems Immunology

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients